Recce Pharmaceuticals has been awarded a grant of US$2 million (approximately $3 million) by the US Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) for development of burn wound treatments. Recce, an ASX-listed company developing synthetic anti-infectives, said in a statement on Monday morning (AEST) that the grant recognised its RECCE 327 Gel (R327G)…
The federal government’s Research and Development (R&D) tax incentive may have highly restrictive rules and definitions which cut the number of companies eligible for assistance, but for early stage and start up companies it can be a godsend. Available to companies turning over less than $20 million – itself a bone of contention with innovative…
Anti-infective drug development company Recce Pharmaceuticals is to test its lead compound RECCE 327 (R327) in a study of topical burn healing in humans. The company has been registered in the Australian New Zealand Clinical Trial Registry (ANZCTR), one of the final stages before Phase I/II clinical trials may begin. The Company’s clinical trial is…
Tests of a drug being commercialised by synthetic antibiotic developer Recce Pharmaceuticals have shown it effective in killing the SARS-CoV-2 virus. Recce told investors that tests conducted by the CSIRO and Doherty Institute with its drug candidate R327 showed a reduction in SARS-CoV-2 viral genome numbers. “Further testing will be required at higher dose levels…
Anti-infective drug developer Recce Pharmaceuticals has received commitments from investors for $27,950,000 to be raised in a placement of shares. The capital raising will fast track commercialisation activities and fund human clinical trials. The company has been developing broad spectrum synthetic drugs which have achieved ‘positive results’ in pre-clinical laboratory and animal tests on E.…
Recce Pharmaceuticals will trial its anti-infective agents RECCE 327 and RECCE 529 against SARS- CoV-2. The company has teamed with North Carolina’s Path BioAnalytics to trial its broad-spectrum synthetic antibiotics which the company is commercialising to defeat resistant superbugs, Researchers at PBA will evaluate the company’s drug candidates in an ‘ex vivo respiratory organoid model…
Medical technology company Recce Limited (ASX: RCE) has won US patent protection for a range of new synthetic antibiotics it has developed and manufactured in Australia. The company announced that the US Patents and Trade Marks Office had granted patents over 23 claims for patent including its lead drug candidate, RECCE 327. The company has…
Orthocell’s strong sales growth Tissue regeneration technology developer Orthocell has announced sales growth across its product portfolio, with total revenue for FY24 of $6.72 million – up 30.40 percent from FY23. Record revenue of $1.84m was achieved for the June 24 Quarter, up 14.41 percent. With Striate+ currently sold in the US, Europe/UK, Australia and…
Quickstep’s new drone order from Carbonix Composites manufacturer Quickstep has announced a significant follow-on order from Australian partner and advanced drone development company Carbonix. The urgent requirement for 40 Volanti airframes and associated non-recurring engineering is the largest yet received from Carbonix for this drone type. Valued at $1.35 million the order is scheduled to…
Archer moves biochip graphene sensor to commercial fab Semiconductor company Archer Materials has announced completion of a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. Archer is transferring its first-generation graphene field effect transistor (“gFET”) design to a foundry partner, …
